Table 1.
Characteristics of the 106 patients with pediatric acute myeloid leukemia
| Clinical variables | Patients (n, %) |
MiR-100 expression (n, %)
|
P | |
|---|---|---|---|---|
| Low | High | |||
| Sex | ||||
| Male | 58 (54.7) | 23 (39.7) | 35 (60.3) | 0.6 |
| Female | 48 (45.3) | 15 (31.3) | 35 (68.7) | |
| Age (years) | ||||
| >6 | 40 (37.7) | 10 (25.0) | 30 (75.0) | 0.2 |
| ≤6 | 66 (62.3) | 26 (39.4) | 40 (60.6) | |
| Leukocytes (/μL) | ||||
| >10,000 | 66 (62.3) | 22 (33.3) | 44 (66.7) | 0.6 |
| ≤10,000 | 40 (37.7) | 14 (35.0) | 26 (65.0) | |
| FAB classification | ||||
| M1–M6 | 96 (90.6) | 35 (36.5) | 61 (63.5) | 0.001 |
| M7 | 10 (9.4) | 1 (10.0) | 9 (90.0) | |
| Extramedullary disease | ||||
| Absent | 80 (75.5) | 31 (38.8) | 49 (61.2) | 0.008 |
| Present | 26 (24.5) | 5 (19.2) | 21 (80.8) | |
| Cytogenetics* | ||||
| Favorable | 35 (33.0) | 20 (20.0) | 15 (80.0) | 0.3 |
| Intermediate | 52 (49.1) | 9 (17.3) | 43 (82.7) | |
| Unfavorable | 19 (17.9) | 7 (36.8) | 12 (63.2) | |
| Day 7 response to treatment | ||||
| Favorable | 65 (61.3) | 26 (40.0) | 39 (60.0) | 0.01 |
| Unfavorable | 41 (38.7) | 10 (23.3) | 31 (76.7) | |
Notes:
*
All patients were divided into three cytogenetic risk groups: favorable (inv[16], t[16;16], t[9;11], t[8;21]) (2,17); intermediate (normal cytogenetics or not classifiable as favorable or unfavorable); and unfavorable (−7, −5, del [5q], abnormal 3q, or complex karyotype) (2,17).
Abbreviations: MiR-100, microRNA-100; FAB, French–American–British.